Search

Danaher Corp

Suletud

SektorTervishoid

191.98 -0.1

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

189.24

Max

193.94

Põhinäitajad

By Trading Economics

Sissetulek

-168M

1B

Müük

-887M

6B

P/E

Sektori keskmine

39.511

62.58

Aktsiakasum

2.06

Dividenditootlus

0.67

Kasumimarginaal

17.291

Töötajad

58,000

EBITDA

-560M

1.5B

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+14.17% upside

Dividendid

By Acuity

Dividenditootlus

Sektori keskmine

0.67%

2.19%

Järgmine tulemuste avaldamine

20. okt 2026

Järgmine dividendimakse kuupäev

31. juuli 2026

Järgmine aktsia dividendi kuupäev (ex-date)

25. sept 2026

Turustatistika

By TradingEconomics

Turukapital

4B

142B

Eelmine avamishind

192.08

Eelmine sulgemishind

191.98

Uudiste sentiment

By Acuity

47%

53%

151 / 340 Pingereas Healthcare

Danaher Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. juuli 2026, 20:06 UTC

News

Danaher Corp shares are lower amid concerns over reduced sales growth in its biotechnology segment, despite raising full-year earnings guidance to $8.45-$8.60.

23. juuli 2026, 10:01 UTC

Danaher Corp shares are lower in pre-market trading, continuing a decline since Wednesday's close and remaining below the 20-day moving average.

22. juuli 2026, 22:01 UTC

Danaher Corp shares are trading lower in after-market hours, continuing a trend of six consecutive sessions finishing lower amid rising crude oil prices and market volatility.

21. juuli 2026, 19:41 UTC

News
Social Media

Danaher Corp shares are lower after the company issued a cautious fiscal 2026 revenue growth forecast despite reporting better-than-expected second-quarter earnings and revenues.

20. juuli 2026, 23:41 UTC

Danaher Corp shares declined in after-market trading, continuing a trend of lower finishes amid concerns over economic momentum and a drop in the leading economic index.

Võrdlus sarnastega

Hinnamuutus

Danaher Corp Prognoos

Hinnasiht

By TipRanks

14.17% tõus

12 kuu keskmine prognoos

Keskmine 219.78 USD  14.17%

Kõrge 240 USD

Madal 195 USD

Põhineb 20 Wall Streeti analüütiku instrumendi Danaher Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

20 ratings

17

Osta

3

Hoia

0

Müü

Sentiment

By Acuity

151 / 340 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.
help-icon Live chat